ArticleJournal of clinical hypertension (Greenwich, Conn.)2007
Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.Journal of general internal medicine · 2012Pooled it
- Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Cardiovascular diabetology · 2009Pooled it
- Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.Clinical drug investigation · 2011Trial
- Persistence to antihypertensive drug classes in uncomplicated hypertension: a nationwide Swedish cohort study.EClinicalMedicine · 2026Article
- Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Article
- Article
- Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD).Medicine · 2016Observational
- Achieving Adherence After First-Line Antihypertensive Treatment: Should Fixed-Dose Combinations Receive Priority?Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data.PharmacoEconomics · 2016Article
- Persistence and compliance with newly initiated antihypertensive drug treatment in patients with chronic kidney disease.Patient preference and adherence · 2016Article
- Persistence with Antihypertensive Medications in Uncomplicated Treatment-Naïve Patients: Effects of Initial Therapeutic Classes.Journal of Korean medical science · 2015Article
- Antihypertensive medication persistence 1-year post-stroke hospitalization.Journal of clinical hypertension (Greenwich, Conn.) · 2014Article
- Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.Journal of human hypertension · 2014Article
- Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.Clinical drug investigation · 2014Observational
- Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010.Journal of general internal medicine · 2014Article
- Diuretics for hypertension-reasons for a contradiction in primary care prescribing behavior: a qualitative study.Journal of clinical hypertension (Greenwich, Conn.) · 2012Article
- Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2009Review
- Predictors of first-fill adherence for patients with hypertension.American journal of hypertension · 2009Article
- Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >or=65 years.Drugs & aging · 2009Review
- Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.BMC family practice · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihypertensive treatment regimen persistence and compliance were measured using a retrospective cohort study of pharmacy claims data. Newly treated patients receiving monotherapy with angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), beta-blockers (BBs), or diuretics were followed for 1 year (N=242,882). A higher proportion of ARB patients (51.9%) were persistent in taking prescribed medication compared with those in the ACEI (48.0%), BB (40.3%), CCB (38.3%), and diuretic groups (29.9%). Compared with patients receiving diuretics, those receiving ARBs (hazard ratio [HR], 0.593; P<.0001), ACEIs (HR, 0.640; P<.0001), CCBs (HR, 0.859; P<.0001), and BBs (HR, 0.819; P<.0001) were all less likely to discontinue therapy. Compliance was similar in ACEI and ARB patients, but patients receiving ARBs and ACEIs had better compliance than those receiving BBs, CCBs, or diuretics. The lesser degree of compliance and persistence observed in patients receiving diuretics compared with other antihypertensive medications may have public health as well as cost implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.